Stocksigma LogoStocksigma Logo

Evonile Pharma Reports Q2 FY27 Results and ₹800 Crore Debt Clarification

Evonile Pharma Limited (formerly Novartis India) clarified its total outstanding bank debt and financial indebtedness at ₹800 crore as of 30th Sep'26 with

Evonile Pharma Reports Q2 FY27 Results and ₹800 Crore Debt Clarification

Novartis India Ltd · Financial Result · 04 Nov 2026, 5:38 am

Evonile Pharma Reports Q2 FY27 Results and ₹800 Crore Debt Clarification Evonile Pharma Limited (formerly Novartis India) clarified its total outstanding bank debt and financial indebtedness at ₹800 crore as of 30th Sep'26 with zero defaults. For Q2 ended 30th Sep'26, revenue from operations dropped 37.9% YoY to ₹560.5 million. The company posted a net loss of ₹775.4 million versus a profit of ₹242.2 million in Q2 FY26, impacted by an exceptional item of ₹682.6 million following the termination of distribution arrangements. It also capitalized ₹12,900.0 million in intangible assets for trademark acquisitions.

Original exchange filing (PDF)

More announcements from Novartis India Ltd

All Novartis India Ltd announcements